The US Food and Drug Administration (FDA) has ordered manufacturers of popular weight-loss and diabetes medications to include new safety warnings about a rare eye condition that can cause sudden and permanent vision loss.
The regulatory update, announced on November 9, 2026, concerns glucagon-like peptide-1 (GLP-1) medications, a class of drugs that has gained popularity among people seeking medical treatment for obesity and type 2 diabetes.
The warning highlights a potential link between the medications and non-arteritic anterior ischaemic optic neuropathy (NAION), a condition that damages the optic nerve by disrupting its blood supply.
Popular medications affected include semaglutide brands Ozempic, Wegovy and Rybelsus, as well as tirzepatide brands Mounjaro and Zepbound. Other approved GLP-1 medications are also covered by the regulatory update.
The decision introduces an additional safety consideration for millions of patients who use the drugs to manage their weight or blood sugar levels.
NAION, commonly described as an eye stroke, occurs when reduced blood flow damages the front portion of the optic nerve.
The optic nerve carries visual information from the eye to the brain. When it loses its blood supply, the nerve can suffer permanent damage, affecting a person’s ability to see.
Unlike some other eye conditions, NAION often develops without pain. Patients may first notice a problem when they wake up and discover that their vision has suddenly deteriorated in one eye.
The FDA identified several symptoms that patients should watch for, including sudden painless vision loss, blurred vision, missing portions of their field of vision, blind spots, tunnel vision and changes in colour perception.
In its November 9 safety communication, the FDA stated: “NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss.”
The regulator advised patients experiencing these symptoms to contact their healthcare professionals immediately and seek an eye examination.
The new requirement covers all approved GLP-1 receptor agonist medications in the United States, rather than targeting one manufacturer or a single drug.
The affected medications include:
- Semaglutide: Ozempic, Wegovy and Rybelsus.
- Tirzepatide: Mounjaro and Zepbound. These medicines act on both GIP and GLP-1 receptors.
- Liraglutide: Victoza and Saxenda.
- Dulaglutide: Trulicity.
- Lixisenatide: Used in Soliqua, a combination medication.
- Orforglipron: Foundayo, an oral weight-management medication.
The FDA’s list also includes other products containing GLP-1 receptor agonists, such as Xultophy and exenatide products.
These medications work by mimicking the natural GLP-1 hormone, which helps regulate blood sugar after meals and influences appetite and food intake.
Doctors prescribe them to manage type 2 diabetes and obesity. Some also have additional approved uses, including reducing cardiovascular risks and treating certain complications associated with obesity and diabetes.
Despite the warning, the FDA stressed that NAION remains rare among people taking the medications.
The FDA has urged patients not to ignore sudden changes in their eyesight, particularly when using GLP-1 medications.
People taking the drugs should seek immediate medical attention if they experience sudden vision loss, blurred vision, blind spots or changes in colour perception.
The regulator also advised doctors to refer patients suspected of having NAION to an ophthalmologist for further assessment.
For patients diagnosed with the condition, healthcare professionals should consider discontinuing the GLP-1 medication unless the benefits of continuing treatment clearly outweigh the risks.
However, patients who have not experienced the condition should discuss their concerns and treatment options with their doctors rather than independently changing their medication.
The FDA also identified people with a previous NAION diagnosis as being at increased risk of experiencing another episode.
The new requirement means manufacturers must update the Warnings and Precautions section of their medication labels to inform patients and healthcare professionals about the potential eye complication.
The decision adds another safety consideration to the growing use of weight-loss injections, as regulators continue to assess the long-term effects of medications that have transformed obesity and diabetes treatment.
